Polyoxidonium, 5 pcs., 1ml, 6 mg, solution for injection and topical use

Compound

One tablet of Polyoxidonium contains 12 mg of the active substance azoximer bromide , as well as potato starch (Amylum solani), lactose monohydrate (Lactose monohydrate), stearic acid (Acidum stearicum) as auxiliary components.
One bottle of lyophilisate contains 6 mg of active ingredient, as well as mannitol (E421 Mannit), povidone (Povidonum) and beta-carotene (Betacarotenum) as auxiliary components.

To make one rectal-vaginal suppository, 6 or 12 mg of active ingredient and auxiliary components are used: mannitol (E421 Mannit), povidone (Povidonum), beta-carotene (Betacarotenum), cocoa butter (Butyrum Cacao).

Release form

Polyoxidonium has three dosage forms:

• pills;
• rectal-vaginal suppositories;
• lyophilized powder.

The suppositories are torpedo-shaped, light yellow in color and have a specific smell of cocoa butter.

The tablets are flat-cylindrical, each of them has a chamfer. Their color can vary from yellowish-white to orange-yellow. The presence of slightly noticeable particles of more intense color is allowed in tablets.

Pharmacodynamics and pharmacokinetics

Polyoxidonium (or azoximer bromide ) helps increase the body's resistance to infections caused by viruses, bacteria or fungi.

The mechanism of its action is associated with the substance’s ability to influence phagocytic cells and NK cells (natural or natural killer cells), as well as stimulate the process of antibody formation.

The drug helps restore the immune status in secondary immunodeficiency conditions, caused by various types of infections, injuries, burns, malignant tumors , complications after surgical interventions, treatment with chemotherapy drugs, including cytostatic agents and steroid hormones .

Along with the immunocorrective effect of azoximer, bromide also has a pronounced detoxifying effect, which is due to the structure and high-molecular nature of this substance.

The result of its effect on the body is an increase in the resistance of cell membranes to the cytotoxic (causing damage to cells up to their death) action of drugs and chemicals, as well as a decrease in the toxicity of the latter.

Prescribing Polyoxidonium in combination with other drugs significantly increases the effectiveness of therapy, shortens its duration, allows you to reduce doses or completely avoid the use of antibiotics , bronchodilators and glucocorticosteroids , and helps to increase the period of remission (that is, the period of weakening or complete disappearance of the symptoms of the disease).

Polyoxidonium is well tolerated by patients, does not exhibit mitogenic or polyclonal activity, does not have antigenic properties, does not provoke the development of allergies , mutations and other defects in fetal development , does not have a teratogenic effect on the developing fetus, and has no carcinogenic or embryotoxic properties.

Azoximer bromide is characterized by a high bioavailability, which is about 89 percent. When administered intramuscularly, Cmax in blood plasma is observed 40 minutes after injection.

The substance is distributed fairly quickly in tissues. In the body , azoximer bromide is biotransformed. Its elimination is carried out mainly by the kidneys.

Instructions for use of the drug Polyoxidonium®, solution for injection and topical use

Azoximer bromide has a complex effect: immunomodulatory, detoxifying, antioxidant, moderate anti-inflammatory. The basis of the mechanism of immunomodulatory action of Azoximer bromide is a direct effect on phagocytic cells and natural killer cells, as well as stimulation of antibody formation and the synthesis of interferon-alpha and interferon-gamma. The detoxification and antioxidant properties of Azoximer bromide are largely determined by the structure and high-molecular nature of the drug. Azoximer bromide increases the body's resistance to local and generalized infections of bacterial, fungal and viral etiology. Restores immunity in secondary immunodeficiency conditions caused by various infections, injuries, complications after surgery, burns, autoimmune diseases, malignant neoplasms, the use of chemotherapeutic agents, cytostatics, steroid hormones. The use of the drug Polyoxidonium® against the background of secondary immunodeficiency states can increase the effectiveness and shorten the duration of treatment, significantly reduce the use of antibiotics, bronchodilators, glucocorticosteroids, and extend the period of remission. The inclusion of the drug Polyoxidonium® in the complex therapy of cancer patients reduces intoxication during chemotherapy and radiation therapy, in most cases allows for standard therapy without changing the regimen due to the development of infectious complications and side effects (myelosuppression, vomiting, diarrhea, cystitis, colitis and others ). A characteristic feature of Azoximer bromide when applied locally (intranasally, sublingually) is the ability to activate factors of the body's early defense against infection: the drug stimulates the bactericidal properties of neutrophils, macrophages, enhances their ability to absorb bacteria, increases the bactericidal properties of saliva and secretions of the mucous membranes of the upper respiratory tract. Azoximer bromide blocks soluble toxic substances and microparticles, has the ability to remove toxins and heavy metal salts from the body, and inhibits lipid peroxidation both by intercepting free radicals and by eliminating catalytically active Fe2+ ions. Azoximer bromide reduces the inflammatory response by normalizing the synthesis of pro- and anti-inflammatory cytokines. Azoximer bromide is well tolerated, does not have mitogenic, polyclonal activity, antigenic properties, does not have allergenic, mutagenic, embryotoxic, teratogenic and carcinogenic effects. Azoximer bromide is odorless and tasteless, and does not have a local irritant effect when applied to the mucous membranes of the nose and oropharynx.

Indications for use

Indications for use of tablets

For adult patients and adolescents over 12 years of age, Polyoxidonium tablets are prescribed, as a rule, as an addition to the current therapy.

The medicine is indicated for acute and chronic recurrent inflammatory and infectious diseases in the oral cavity, paranasal sinuses, upper respiratory tract, inner and middle ear.

For immunocompromised patients (patients with secondary immune deficiency ), Polyoxidonium is prescribed to be taken sublingually as a monotherapeutic agent for the prevention of influenza and other acute respiratory infections in the period preceding seasonal epidemics.

Indications for use of lyophilisate

The solution, which is prepared from lyophilized powder, is intended for injection into a muscle or vein, as well as for external use.

For adult patients it is prescribed as an addition to the main therapy for:

• inflammatory diseases of various origins resistant to standard therapy during their exacerbation and during remission (including chronic and recurrent diseases);
• rheumatoid arthritis (if the patient has undergone long-term treatment with immunosuppressive drugs );
• complicated by acute respiratory infections or acute respiratory viral infections, rheumatoid arthritis ;
• infectious diseases occurring in acute or chronic form, provoked by the activity of viruses or bacteria (including diseases of the urogenital tract);
• tuberculosis;
• diseases of an allergic nature, which are complicated by chronic recurrent bacterial or viral infection;
• conditions arising during radiation or chemotherapy of malignant neoplasms.

As an addition to the main therapy, Polyoxidonium is used in cases where it is necessary to reduce the hepato- and nephrotoxic effects of drugs . Since the drug stimulates tissue regeneration, its use is also advisable for the treatment of burns , bone fractures and trophic ulcers .

Monotherapy using Polyoxidonium injections is indicated:

• to prevent the development of infectious complications in the postoperative period;
• for the correction of secondary immunodeficiency , which are a consequence of the aging of the body or the adverse effects of external factors;
• for preventive purposes to prevent influenza and acute respiratory infections .

Children can use Polyoxidonium in the form of a solution from six months. The drug is prescribed as an addition to the main therapy:

• for infectious and inflammatory diseases (including ENT diseases - adenoid vegetations , ARVI , inflammation of the pharyngeal tonsils, nasal mucosa or paranasal sinuses, etc.);
• for acute allergic reactions and toxic-allergic lesions;
• bronchial asthma occurring with complications ;
• atopic dermatitis complicated by purulent infection ;
• in conditions accompanied by disruption of the normal bacterial composition of the intestine;
• for the rehabilitation of children with CBD syndrome ;
• for preventive purposes to prevent influenza and acute respiratory infections .

Indications for use of suppositories

Indications for the drug in the form of suppositories for rectal and vaginal use are the same as for the solution. The use of suppositories is advisable for inflammatory diseases of various localizations and various etiologies, arthritis , for the treatment of tumors , for the prevention of infectious diseases in children and the elderly.

Polyoxidonium suppositories are often prescribed for the treatment of female diseases. Suppositories in gynecology are prescribed for cervical erosion , endometritis , leukoplakia , colpitis , salpingitis , dysplasia , etc.

Longidaza lyophilisate for the preparation of solution for injection 3000 IU ampoules 5 pcs

Longidaza® is used subcutaneously (near the site of the lesion or under scar tissue) or intramuscularly at a dose of 3000 IU in a course of 5 to 25 injections (depending on the disease) with an interval between injections of 3 to 10 days.

Methods of application are selected by the doctor depending on the diagnosis, severity of the disease, clinical course, and age of the patient. If necessary, a repeat course is recommended after 2-3 months.

In the case of treatment of diseases accompanied by a severe chronic productive process in the connective tissue, after a standard course, long-term maintenance therapy with Longidaza® 3000 IU is recommended with breaks between injections of 10-14 days.

To increase the bioavailability of drugs and diagnostic agents, a dose of 1500 IU is recommended with preliminary intramuscular or subcutaneous administration 10-15 minutes into the same place as the main drug.

Dilution: 1. The contents of the ampoule or bottle of Longidaza® 3000 IU are dissolved in 1.0-2.0 ml of procaine solution (0.25% or 0.5%). In case of intolerance to procaine, Longidaza® is dissolved in the same volume of 0.9% sodium chloride solution for injection or water for injection. 2. When used to increase bioavailability, the contents of the ampoule or vial of Longidaza® 3000 IU are dissolved in 2.0 ml, and with a dosage of 1500 IU in 1.0 ml of 0.9% sodium chloride solution for injection. The solvent must be introduced into the bottle or ampoule slowly, wait for 2-3 minutes, and carefully mix without shaking so as not to foam the protein. The prepared solution for parenteral administration cannot be stored. Do not administer intravenously!

Recommended regimens and doses:

For the prevention of adhesive disease and severe scarring after surgical interventions on the abdominal and pelvic organs, intramuscularly at a dosage of 3000 IU once every 3 days for a course of 5 injections. If necessary, the use of Longidaza® can be continued with a total course of up to 10 injections administered once every 5 days.

For treatment.

in gynecology: - adhesions in the pelvis for inflammatory diseases of the internal genital organs, intramuscularly at 3000 IU once every 3-5 days for a course of 10-15 injections; — tubo-peritoneal infertility intramuscularly at 3000 IU in a general course of up to 15 injections: the first 5 injections 1 time in 3 days, then 1 time in 5 days;

in urology: - chronic prostatitis intramuscularly at 3000 IU once every 5 days, a course of 10-15 injections; — interstitial cystitis intramuscularly, 3000 IU once every 5 days, for a course of up to 10 injections;

in surgery: - adhesive disease after surgical interventions on the abdominal organs intramuscularly at a dosage of 3000 IU once every 3-5 days for a course of 10 to 15 injections; - long-term non-healing wounds intramuscularly at a dosage of 3000 IU once every 5 days for a course of 5-10 injections;

in dermatovenereology, cosmetology: - limited scleroderma intramuscularly at 3000-4500 IU once every 3-5 days for a course of up to 20 injections. The dosage and course are selected individually depending on the clinical course, stage, location of the disease and the individual characteristics of the patient; - keloid, hypertrophic and developing scars after pyoderma, burns, operations, injuries: intra-scar or subcutaneous injection near the site of the lesion once every 3 days, for a course of up to 15 injections at a dosage of 3000-4500 IU. The volume of dilution of Longidaza® is selected by the doctor depending on the number of injection points. If necessary, the course can be continued according to the scheme once every 5 days up to 25 injections. Depending on the area of ​​skin damage and the age of scar formation, it is possible to alternate subcutaneous and intramuscular administration once every 5 days at a dosage of 3000 IU, for a course of up to 20 injections.

in pulmonology and phthisiology: - pneumosclerosis intramuscularly at 3000 IU once every 5 days for a course of 10 injections; — fibrosing alveolitis intramuscularly at a dosage of 3000 IU once every 5 days for a course of 15 injections, then maintenance therapy once every 10 days for a total course of up to 25 injections; — tuberculosis intramuscularly at a dosage of 3000 IU once every 5 days for a course of up to 25 injections; depending on the clinical picture and severity of the disease, long-term therapy is possible (from 6 months to 1 year at a dosage of 3000 IU once every 10 days);

in orthopedics: - joint contractures subcutaneously near the lesion site at a dosage of 3000 IU once every 3 days for a course of 5 to 15 injections; - arthrosis, ankylosing spondylitis subcutaneously near the site of the lesion at a dosage of 3000 IU once every 3 days for a course of up to 15 injections; if necessary, treatment can be continued with injections once every 5 days. The duration of maintenance therapy is selected by the doctor depending on the severity of the disease; — hematomas subcutaneously near the site of the lesion at a dosage of 3000 IU once every 3 days for a course of up to 5 injections;

to increase bioavailability: when administered subcutaneously or intramuscularly with diagnostic or medicinal drugs (antibiotics, chemotherapy drugs, anesthetics, etc.). Longidaza® is pre-administered 10-15 minutes in advance at a dosage of 1500 IU in the same way and in the same place as the main drug.

Instructions for Polyoxidonium (Method and dosage)

The dose and route of administration will be determined depending on the diagnosis, the characteristics of the course of the disease and the age of the patient.

Instructions for Polyoxidonium tablets

The tablets are intended for sublingual (under the tongue) or oral (inside) administration. They are drunk daily, once, twice or three times a day (the frequency of doses depends on the nature of the disease and the severity of the clinical picture) 20-30 minutes before meals.

A single dose of the drug for adults is 1 tablet (equivalent to 12 mg of azoximer bromide ), children from 3 to 10 years old are prescribed to take 0.5 tablets per dose.

Instructions for use of Polyoxidonium in the form of lyophilisate

The solution is administered intramuscularly or by drip into a vein, and used intranasally.

For the treatment of acute inflammatory diseases, the drug is administered daily for 3 days at a dose of 6 mg. Further, Polyoxidonium injections continue to be given every other day. Typically, the patient requires five to ten injections.

For the treatment of chronic inflammatory diseases and rheumatoid arthritis , the first 5 injections are given every other day, then the drug is continued to be administered 2 times a week. A single dose of the active substance is 6 mg. The full course involves at least ten injections.

Patients diagnosed with tuberculosis are prescribed 6 mg of the drug 2 times a week. The full course is from ten to twenty injections.

For patients with diseases of the urogenital tract, ten injections are recommended (every other day). Single dose - 6 mg. Therapy is supplemented with the prescription of chemotherapy drugs .

Patients with chronic recurrent herpes . In this case, Polyoxidonium is prescribed in combination with stimulators of endogenous interferon synthesis, antiviral agents, and interferon .

Therapy for complicated allergic diseases involves administering five single doses of the drug (6 mg) to the patient. The first two injections are recommended to be given daily, the remaining three injections are given every other day.

For allergies and toxic-allergic lesions, intravenous administration of a dose of 6-12 mg is indicated in combination with drugs that have an antiallergic effect (including Clemastine ).

For patients undergoing chemotherapy (as well as after its completion), to reduce the specific effect of chemotherapeutic agents, the drug is prescribed in a dose of 6-12 mg. It is considered optimal to carry out at least ten injections (maintaining a daily interval between them).

To correct the immunodeficiency state after radiation and chemotherapy, after surgical removal of the tumor, the patient is administered a dose of 6 mg 1-2 times a week. The course of treatment is quite long - usually from 2-3 to 12 months.

According to the instructions for use, Polyoxidonium injections are allowed to be administered renal failure

To prepare a solution for intramuscular injection, 6 mg of the active substance (the contents of one ampoule or bottle) is combined with 1.5-2 ml of NaCl solution or water for injection.

A solution for drip administration into a vein is prepared by mixing the contents of one ampoule or bottle with 3 ml of NaCl solution, Hemodez , plasma replacement drug Reopoliglucin or 5% glucose solution. The resulting solution must be transferred under sterile conditions into a bottle with any of the above solutions with a volume of 0.2-0.4 liters.

The solution for parenteral administration must be used immediately after preparation; it cannot be stored.

Intranasal use is indicated for acute and chronic infectious ENT diseases, to accelerate the regeneration of mucous membranes, to prevent the development of complications and relapses of diseases, to prevent influenza and respiratory diseases.

To prepare a nasal solution, 6 mg of lyophilisate is combined with one milliliter (20 drops) of distilled water, NaCl solution or ordinary boiled water. In this case, the temperature of the liquid should be room temperature.

The solution is injected into each nasal passage at least 3-4 times during the day, leaving 2-3 hours between instillations. Single dose: 1 to 3 drops in each nostril. Treatment is continued for five to ten days.

After dilution, the drug remains stable for 24 hours, after which it cannot be used.

Polyoxidonium suppositories, instructions for use

Suppositories 12 mg and 6 mg are administered rectally, after the bowel cleansing procedure, once a day (before bedtime). Single dose - one suppository. The scheme of their administration is as follows: one daily for the first 3 days, then one at a time after 2 days. A full course requires 10 suppositories.

Intravaginal use is indicated for the treatment of gynecological diseases: dysplasia , erosion , cervical lekoplakia , colpitis , adnexitis , endometritis , as well as diseases provoked by human papillomavirus (HPV).

Treatment involves daily administration of one suppository for three days with a dosage of the active substance of 12 mg, after which the suppositories continue to be administered every other day. The course is carried out using 10 suppositories. In cases where it is appropriate, the course of treatment can be repeated after 3-4 months.

For patients diagnosed with chronic immune deficiency (including patients in whom such a condition resulted from cancer ), Polyoxidonium is prescribed as a maintenance agent in a dose of 6 or 12 mg (according to the doctor’s indications) 1-2 times a week. The treatment is long-term.

Polyoxidonium, 5 pcs., 1ml, 6 mg, solution for injection and topical use

Pills.

Orally

and
sublingually
, 20–30 minutes before meals, daily 1, 2 or 3 times a day.

Adults - in doses of 12 or 24 mg, adolescents - in doses of 12 mg. The method and dosage regimen is determined by the doctor, depending on the diagnosis, severity and severity of the process.

Sublingual:

- for inflammatory processes of the oropharynx (bacterial, viral and fungal in nature):

1 table each 2 times a day every 12 hours, for 10–14 days. For severe forms of herpetic and fungal infections of the oral cavity - 1 table. 3 times a day every 8 hours for 15 days;

- for chronic diseases of the paranasal sinuses and chronic otitis media:

1 table each 2 times a day every 12 hours, for 5–10 days;

- for chronic tonsillitis:

1 table each 3 times a day every 8 hours for 10–15 days;

- for chronic diseases of the upper respiratory tract:

adults - 2 tablets. (24 mg) 2 times a day, adolescents - 1 tablet. (12 mg) 2 times a day, every 12 hours, for 10–14 days;

- for the prevention of influenza and acute respiratory infections:

immunocompromised persons who suffer from acute respiratory infections more than 4 times a year; in the pre-epidemic period, adults - 2 tables. (24 mg), adolescents - 1 tablet. (12 mg) 2 times a day every 12 hours, for 10–15 days.

Orally:

— for chronic diseases of the upper respiratory tract:

adults - 2 tablets. (24 mg) 2 times a day after 12 hours, for adolescents - 1 tablet. (12 mg) 2 times a day, every 12 hours, for 10–14 days.

Lyophilisate for the preparation of solution for injection and topical use

Adults

Parenteral, intranasal

. Methods of application are selected by the doctor depending on the severity of the disease and the age of the patient.

IM or IV (drip):

the drug is prescribed to adults in doses of 6–12 mg 1 time per day, daily, every other day or 1–2 times a week, depending on the diagnosis and severity of the disease.

For intramuscular administration, the contents of the ampoule or bottle are dissolved in 1.5–2 ml of 0.9% sodium chloride solution or water for injection. For intravenous (drip) administration, the drug is dissolved in 2 ml of 0.9% sodium chloride solution, Hemodez-N, Reopoliglucin or 5% dextrose solution, then sterilely transferred into a bottle with the indicated solutions of 200–400 ml.

The prepared solution for parenteral administration cannot be stored.

Intranasally:

a dose of 6 mg is dissolved in 1 ml (20 drops) of distilled water, 0.9% sodium chloride solution or boiled water at room temperature.

Recommended treatment regimens for adults

Parenterally:

- for acute inflammatory diseases:

6 mg daily for 3 days, then every other day with a general course of 5–10 injections;

- for chronic inflammatory diseases:

6 mg every other day for 5 injections, then 2 times a week for a course of at least 10 injections;

- for tuberculosis:

6–12 mg 2 times a week for a course of 10–20 injections;

- in patients with acute and chronic urogenital diseases:

6 mg every other day for a course of 10 injections in combination with chemotherapy;

- for chronic recurrent herpes:

6 mg every other day for a course of 10 injections in combination with antiviral drugs, interferons and/or inducers of interferon synthesis;

- for the treatment of complicated forms of allergic diseases:

6 mg, course of 5 injections - the first 2 injections daily, then every other day. For acute allergic and toxic-allergic conditions, administer 6–12 mg intravenously in combination with other antiallergic drugs;

- for rheumatoid arthritis:

6 mg every other day - 5 injections, then 2 times a week for a course of at least 10 injections.

In cancer patients:

- before and during chemotherapy to reduce the immunosuppressive, hepato- and nephrotoxic effects of chemotherapy drugs - 6-12 mg every other day for a course of at least 10 injections, then the frequency of administration is determined by the doctor depending on the tolerability and duration of chemotherapy and radiation therapy;

— for the prevention of the immunosuppressive effect of the tumor, for the correction of immunodeficiency after chemotherapy and radiation therapy, after surgical removal of the tumor, long-term use of the drug Polyoxidonium® is indicated (from 2-3 months to 1 year) - 6-12 mg 1-2 times a week.

In patients with acute renal failure:

prescribed no more than 2 times a week.

Intranasally

6 mg/day is prescribed for the treatment of acute and chronic infections of the ENT organs, to enhance the regenerative processes of the mucous membranes, to prevent complications and relapses of diseases, to prevent influenza and acute respiratory infections. 3 drops in each nasal passage every 2–3 hours (3 times a day) for 5–10 days.

Children

Parenteral, intranasal, sublingual

. Methods of application are selected by the doctor depending on the diagnosis, severity of the disease, age and body weight of the patient.

Parenterally

the drug is prescribed to children from 6 months at a dose of 3 mg (im or intravenous drip 0.1–0.15 mg/kg) daily, every other day or 2 times a week in a course of 5–10 injections (dose calculation is indicated in the table ).

For intramuscular administration, the drug is dissolved in 1 ml of water for injection or 0.9% sodium chloride solution.

For intravenous drip administration, the drug is dissolved in 1.5–2 ml of a sterile 0.9% solution of sodium chloride, Reopoliglucin, Hemodez-N or 5% dextrose solution, sterilely transferred to a bottle with the indicated solutions with a volume of 150–250 ml.

Intranasal and sublingual:

daily at a daily dose of 0.15 mg/kg for 5–10 days. The drug is administered 1–3 drops into one nasal passage or under the tongue after 2–3 hours. To prepare a solution for intranasal and sublingual use, a dose of 3 mg is dissolved in 1 ml (20 drops), a dose of 6 mg is dissolved in 2 ml of distilled water, 0.9% sodium chloride solution or boiled water at room temperature. One drop of the prepared solution (50 μl) contains 0.15 mg of the drug Polyoxidonium®, which is prescribed per 1 kg of child’s body weight.

Store the solution for sublingual and intranasal use in the refrigerator for no more than 7 days. Before use, the pipette containing the solution must be warmed to room temperature (20–25 °C).

Recommended treatment regimens for children:

- for acute inflammatory diseases:

0.1 mg/kg every other day for a course of 5–7 injections;

- for chronic inflammatory diseases:

0.15 mg/kg 2 times a week for a course of up to 10 injections;

- for acute allergic and toxic-allergic conditions:

IV drip at a dose of 0.15 mg/kg in combination with antiallergic drugs;

— for the treatment of complicated forms of allergic diseases in combination with basic therapy:

IM 0.1 mg/kg in a course of 5 injections with an interval of 1–2 days.

Intranasally

administer 1–3 drops into one nasal passage every 2–3 hours (2–4 times a day). For intranasal and sublingual administration, the calculation of the daily dose for children is presented in the table.

Sublingual:

for all indications - daily at a daily dose of 0.15 mg/kg for 10 days, for the treatment of intestinal dysbiosis for 10-20 days. Place 1-3 drops under the tongue every 2-3 hours.

Suppositories

Rectally

or
vaginally
1 supp.
(6 and 12 mg) 1 time per day. The method and dosage regimen is determined by the doctor depending on the diagnosis, severity and severity of the process. Polyoxidonium® can be used rectally
or
vaginally
daily, every other day or 2 times a week.

Polyoxidonium®, suppositories 12 mg

used in adults rectally or vaginally.

Rectally:

1 time per day, 1 sup. (after bowel cleansing).

Vaginally:

for gynecological diseases, 1 supp. Once a day (at night) it is inserted into the vagina in a lying position.

Polyoxidonium®, suppositories 6 mg

used: in children over 6 years old rectally - 1 supp. 1 time per day (after cleansing the intestines), in adults - rectally (after cleansing the intestines) or vaginally (in the vagina in a lying position) as a maintenance dose - 1 supp. 1 time per day (at night).

Standard scheme

use of Polyoxidonium® - 1 supp. (6 or 12 mg) 1 time per day, daily for 3 days, then every other day with a course of 10–20 supp. If necessary, the course of treatment is repeated after 3–4 months.

For patients receiving long-term immunosuppressive therapy, cancer patients with an acquired defect of the immune system - HIV, who have been exposed to radiation, long-term maintenance therapy with Polyoxidonium® is indicated for 2-3 months to 1 year (adults - 12 mg, children over 6 years - 6 mg 1–2 times a week).

Recommended regimens for use as part of complex therapy:

— for chronic infectious and inflammatory diseases:

in the acute stage - according to the standard regimen, in the remission stage - 1 supp. after 1–2 days, the general course is 10–15 supp.;

— in acute infectious processes and to activate regenerative processes (fractures, burns, trophic ulcers):

1 sup. daily, course of treatment - 10–15 sup.;

- for tuberculosis

: according to the standard regimen, the course of treatment is at least 15 supp., then it is possible to use maintenance therapy - 2 supp. per week for a course of 2–3 months;

— against the background of chemotherapy and radiation therapy of tumors

: 1 sup. daily 2-3 days before the start of therapy, then the frequency of suppository administration is determined by the doctor depending on tolerability and duration of chemotherapy and radiation therapy;

— for rehabilitation of frequent (more than 4–5 times a year) and long-term ill persons and for rheumatoid arthritis

: 1 sup. every other day, course of treatment - 10–15 supp.

— for the correction of secondary immunodeficiencies, incl. arising due to aging

: 1 sup. (12 mg) 2 times a week, course - at least 10 supp. 2–3 times a year.

As monotherapy:

- for seasonal prevention of exacerbations of chronic foci of infection, prevention of recurrent herpes infection

: every other day for adults - 6–12 mg, for children - 6 mg. Course - 10 supp.

— for the correction of secondary immunodeficiencies, prevention of influenza and acute respiratory infections

: according to the standard scheme.

— for gynecological diseases
(rectal or vaginal)
: according to the standard regimen.

Analogues of Polyoxidonium

Level 4 ATX code matches:
Ridostin

Roferon A

Leukogen

Genfaxon

Estifan

Septilin

Inferon

Neupogen

Lipoferon

Laifferon

Sodium nucleinate

Intron A

Betaferon

Neupomax

Granocyte

Gepon

Imudon

Grippferon

Immunal

Ingaron

Analogs of the drug by mechanism of action: Actinolysate , Anaferon , Arpetolide , Arpeflu , Affinoleukin , Bestin , Bioaron Broncho- , Vilozen , Gepon , Gerbion , Glutaxim , Isofon , Immunal , Immunofan , Neuroferon , Ribomunil , Taktivin , Florexil , Cycloferon , Cytovir- 3 , Engistol , Polymuramil , Ismigen .

Polyoxidonium for children

In pediatric practice, the use of tablets is allowed from the age of 3, suppositories are used from the age of six, and lyophilisate is used from six months.

For children, Polyoxidonium is prescribed as an addition to the main therapy. Indications for use are acute and chronic infectious and inflammatory diseases (including acute respiratory viral infections and ENT diseases ), allergies and toxic-allergic conditions , complicated by chronic infectious processes in the respiratory tract, bronchial asthma , occurring with complications (including complicated by purulent infection) atopic dermatitis, dysbacteriosis .

For children included in the “ChBD” group, the drug is used to speed up the process of their rehabilitation. In addition, Polyoxidonium has a preventive effect against influenza and colds .

Tablets are taken sublingually or orally at a dose of 6 mg (half a tablet), daily, with a frequency of applications 1, 2 or 3 times a day.

The optimal dose, number and frequency of injections are determined depending on the diagnosis and age of the child:

• For acute inflammatory diseases, five to seven injections are recommended every other day. Dose: 100 mcg/kg. If the disease is chronic, the dose is increased to 150 mcg/kg. The drug is administered every other day. The course involves the administration of up to ten single doses.
• For the treatment of allergies and toxic-allergic conditions, drip administration of the drug into a vein at a dose of 150 mcg/kg is indicated. Therapy is supplemented with the prescription of Clemastine and other drugs that have an antiallergic effect. If the disease occurs with complications, injections are prescribed as an addition to basic therapy. The patient is indicated for 5 intramuscular injections at a dose of 100 mcg/kg. The interval between administrations is 1-2 days.

A solution for intramuscular administration is prepared by dissolving 3 mg of the drug in 1 ml of NaCl solution (water for injection can be used).

A solution for intravenous administration is prepared by diluting 3 mg of the drug in 1.5-2 ml of NaCl solution, 5% glucose solution, Polyglucin or Hemodez , after which, under sterile conditions, it is added to a bottle with one of the indicated solutions in a volume of 0.15-0.25 l.

Intranasal Polyoxidonium is used daily for five to ten days, instilling it at least 3-4 times a day into each nostril in a dose of 1 to 3 drops. The daily dose is 150 mcg/kg body weight. The interval between procedures is 2-3 hours.

To prepare a solution for topical use, add 1 ml (equivalent to 20 drops) of liquid at room temperature (0.9% NaCl solution, distilled or ordinary boiled water) to 3 mg of the drug.

For children, the solution is prescribed at a dose of 150 mcg of the active substance per kilogram of body weight (this amount is contained in one drop of the solution).

The drug is prescribed to be taken sublingually daily for 10 days. The daily dose for all indications is 150 mcg/kg. If the drug is used to treat dysbiosis, the course usually lasts from 10 to 20 days.

The solution is stored in the refrigerator for no more than one week. Before instilling the drug, the pipette with the solution must be warmed to room temperature.

According to the instructions for suppositories for children, the drug in this dosage form can be used rectally to treat patients over 6 years of age. According to the doctor’s indications, suppositories are administered one at a time daily or every other day before bedtime.

Polyoxidonium suppositories for children - reviews confirm this - are an effective remedy, however, the desired effect from their use can only be achieved in cases where the treatment regimen is selected by an experienced doctor and takes into account the characteristics of the disease and the body of a particular child.

Polyoxidonium®

Polyoxidonium® suppositories 6 mg and 12 mg are used rectally and vaginally once a day. The method and dosage regimen is determined by the doctor depending on the diagnosis, severity and severity of the process. Polyoxidonium® can be used rectally and vaginally daily, every other day or 2 times a week.

Polyoxidonium® suppositories 12 mg are used rectally in adults , 1 suppository 1 time per day after bowel cleansing; for gynecological diseases and vaginally, 1 suppository 1 time per day (at night) is inserted into the vagina in a lying position.

Polyoxidonium® suppositories 6 mg are used: in children over 6 years old, 1 suppository rectally 1 time per day after bowel cleansing; in adults, rectally and vaginally as a maintenance dose, 1 suppository 1 time per day (at night) is inserted into the vagina in a lying position.

Standard application scheme

1 suppository 6 mg or 12 mg 1 time per day daily for 3 days, then every other day in a course of 10-20 suppositories.

If necessary, the course of treatment is repeated after 3-4 months.

For patients receiving long-term immunosuppressive therapy, cancer patients, those with an acquired defect of the immune system - HIV, who have been exposed to radiation, long-term maintenance therapy with Polyoxidonium® is indicated for 2-3 months to 1 year (adults 12 mg, children over 6 years old - 6 mg 1 -2 times per week).

Variants of recommended regimens for use as part of complex therapy

For chronic infectious and inflammatory diseases in the acute stage - according to the standard regimen, in the remission stage - 1 suppository every 1-2 days, a total course of 10-15 suppositories.

For acute, infectious processes and to activate regenerative processes (fractures, burns, trophic ulcers) - 1 suppository daily. The course of treatment is 10-15 suppositories;

For tuberculosis - according to the standard regimen. The course of treatment is at least 15 suppositories, then it is possible to use maintenance therapy of 2 suppositories per week for a course of up to 2-3 months;

During chemotherapy and radiation therapy of tumors - 1 suppository daily 2-3 days before the start of the course of therapy. Further, the frequency of administration of suppositories is determined by the doctor depending on the tolerability and duration of chemotherapy and radiation therapy;

For rehabilitation of frequent (more than 4-5 times a year) and long-term ill people and rheumatoid arthritis - 1 suppository every other day. Course of treatment - 10 - 15 suppositories;

To correct secondary immunodeficiencies, including those arising due to aging - 1 suppository 12 mg 2 times a week. Course - at least 10 suppositories 2-3 times a year;

As monotherapy:

For seasonal prevention of exacerbations of chronic foci of infections, for the prevention of recurrent herpetic infections - 6-12 mg every other day in adults, 6 mg in children. Course - 10 suppositories;

For the correction of secondary immunodeficiencies, prevention of influenza and acute respiratory infections - according to the standard scheme;

For gynecological diseases, rectally and vaginally - according to the standard regimen.

Reviews for Polyoxidonium

Reviews about the drug are mostly positive. This is due to the fact that it effectively treats chronic and complicated diseases that cannot be treated with standard therapy.

Reviews of Polyoxidonium suppositories, tablets and solution are evidence of the effectiveness of each of these dosage forms. When using the drug in complex therapy, the patient recovers faster, and the disease proceeds in a much milder form.

Using the medicine as a prophylactic agent for children can reduce the incidence of diseases. Reviews from doctors about Polyoxidonium allow us to conclude that this remedy is truly irreplaceable.

Prescribing suppositories, tablets or nasal solution to children promotes faster adaptation to being in a group (at school or kindergarten). At the same time, children are much less susceptible to infections even during periods of seasonal epidemics.

Most of the positive reviews of Polyoxidonium in suppositories and other dosage forms are due to the fact that the drug is easy to use, well tolerated by children and practically does not cause side effects.

For adults, Polyoxidonium is most often prescribed for the treatment of infectious diseases. The use of suppositories in gynecology in combination with basic therapy not only helps to effectively eliminate the symptoms of the disease, but also significantly increases immunity and, accordingly, helps prevent relapses and complications.

Having analyzed reviews of Polyoxidonium injections, we can confidently say that the drug has a positive effect even in quite complex cases when the patient’s body is weakened by cancer and its treatment.

Rare negative reviews are due to the fact that the drug did not produce visible changes in the patient’s condition, which in some cases may be the result of an incorrectly selected dosage regimen that does not take into account the individual characteristics of the patient’s body.

Reviews note the high cost of Polyoxidonium, however, given that the drug is effective, helps quickly and for a long time, eases the course and reduces the incidence of diseases, does not cause pain when administered (this applies to all dosage forms with the exception of injections, the latter, on the contrary, are very painful) , this “disadvantage” fades into the background for most patients.

Polyoxidonium Lyophilisate, bottle, 5 pcs, 6 mg, for injection, lyophilisate for injection

Pharmacological properties

Immunomodulatory drug. Azoximer bromide has a complex effect: immunomodulatory, detoxifying, antioxidant, anti-inflammatory. Azoximer bromide increases the body's resistance to local and generalized infections of bacterial, fungal and viral etiology. Restores immunity in secondary immunodeficiency conditions caused by various infections, injuries, complications after surgery, burns, autoimmune diseases, malignant neoplasms, the use of chemotherapeutic agents, cytostatics, steroid hormones. The basis of the mechanism of the immunomodulatory effect of azoximer bromide is a direct effect on phagocytic cells and natural killer cells, as well as stimulation of antibody formation. Azoximer bromide is capable of stimulating the synthesis of interferon alpha and interferon gamma, which determines its antiviral effectiveness and the possibility of being prescribed for the prevention and treatment of influenza and ARVI. A characteristic feature of azoximer bromide when applied locally (intranasally, sublingually) is the ability to activate factors of the body's early defense against infection: the drug stimulates the bactericidal properties of neutrophils, macrophages, enhances their ability to absorb bacteria, increases the bactericidal properties of saliva and secretions of the mucous membrane of the upper respiratory tract. Local use of azoximer bromide in the complex treatment of diseases of the ENT organs significantly reduces the duration of acute rhinitis, sinusitis, reduces the risk of intracranial complications of ENT pathologies, as well as the frequency and duration of exacerbations of chronic diseases. The detoxification and antioxidant properties of azoximer bromide are determined by the structure and high-molecular nature of the drug and are not associated with the activation of immune mechanisms. Azoximer bromide blocks soluble toxic substances and microparticles, has the ability to remove toxins and heavy metal salts from the body, and inhibits lipid peroxidation. The combination of antioxidant, antiradical, membrane stabilizing and chelating properties makes azoximer bromide a powerful anti-inflammatory agent. The inclusion of the drug in complex therapy in cancer patients reduces intoxication during chemotherapy and radiation therapy, in most cases allows for standard therapy without changing the regimen due to the development of infectious complications and side effects (myelosuppression, vomiting, diarrhea, cystitis, colitis and others) . The use of azoximer bromide against the background of secondary immunodeficiency states can increase the effectiveness and shorten the duration of treatment, significantly reduce the use of antibiotics, bronchodilators, corticosteroids, and lengthen the period of remission. Azoximer bromide is well tolerated, does not have mitogenic, polyclonal activity, antigenic properties, does not have allergenic, mutagenic, embryotoxic, teratogenic and carcinogenic effects. Azoximer bromide is odorless and tasteless, and does not have a local irritant effect when applied to the mucous membranes of the eyes, nose and oropharynx.

Polyoxidonium price, where to buy

The average price of Polyoxidonium tablets is 540 UAH. The price of Polyoxidonium 12 mg suppositories is 750 UAH, you can buy 6 mg suppositories for an average of 580 UAH. Price of Polyoxidonium in ampoules (6 mg injections) - from 600 to 1200 UAH.

You can buy 12 mg tablets in Moscow for an average of 660-750 rubles. The price of 6 mg ampoules is from 950 rubles. 6 mg suppositories cost approximately 750 rubles, 12 mg suppositories cost 850 rubles.

• Online pharmacies in RussiaRussia
• Online pharmacies in KazakhstanKazakhstan

ZdravCity

• Polyoxidonium tablets 12 mg 10 pcs. Petrovax Pharm NPO LLC
  830 rub. order
• Polyoxidonium suppositories for vaginal. and rectal. input 6 mg 10 pcs. Petrovax Pharm NPO LLC

  962 rub. order

• Polyoxidonium solution d/in. and places. approx. 6mg vial. 1ml No. 5Petrovax Pharm NPO LLC

  RUB 1,453 order

Pharmacy Dialogue

• Polyoxidonium suppositories 6 mg No. 10Petrovax Pharm NPO LLC

  915 rub. order

• Polyoxidonium solution for injection and topical use 6 mg/ml 1 ml No. 5 (bottles) Petrovax Pharm NPO LLC

  RUB 1,378 order

• Polyoxidonium tablets 12 mg No. 10Petrovax Pharm NPO LLC

  RUB 836 order

• Polyoxidonium tablets 12 mg No. 10Petrovax Pharm NPO LLC

  RUR 839 order

• Polyoxidonium tablets 12 mg No. 10Petrovax Pharm NPO LLC

  RUR 839 order

show more